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The Use of FK 506 in New-Onset Type I Diabetes in'Man 
P.B. Carroll, A.G. Tzakis, C. Ricordi, H.R. Rilo, K. Abu-Elmagd, N. Murase, Y-J. Zeng, R. Alejandro, 
D. Mintz, and T.E. Starzl 
"INSULITIS" was recognized as a feature of type I 
diabetes mellitus early in the clinical descriptions. 
accompanied by pathological examination. 1 Thus, an eti-
ologic role for inflammation and immunity in this condition 
was raised quite early. It is now appreciated that the 
disease may present abruptly, but studies of patients with 
new onset diabetes and their family members2- 5 have 
clarified that the destruction of B cells proceeds over 
months to years. As a direct result of these studies. the 
current view of the pathogenesis of diabetes is that it 
features a protracted prodromal phase that occurs after an 
unknown factor that initiates the autoimmune attack 
against the B cells.6 During the prodromal period. there is 
evidence of immune response directed against the B cell 
andior its secretory products.7- 10 loss of first-phase insulin 
release, and onset of clinical symptoms when sufficient 
B-cell destruction occurs. Based on the hypothesis that 
type I diabetes is. in most instances. an autoimmune 
disease. clinical trials have been undertaken with immu-
nomodulatory and immunosuppressive treatments. Few 
studies showed an impact to alter the natural course of the 
disease. although some agents appeared to prolong and 
preserve endogenous insulin secretion. 11-19 The definitive 
studies that finally clarified the autoimmune nature of type 
I diabetes mellitus. and showed an effect of immunosup-
pression to induce remissions (noninsulin requiring state) 
in significant numbers of patients and alter the natural 
course of this disease. were the pilot and randomized trials 
employing cyclosporine (Cy A). 20-22 The long-term out-
come of patients who initially achieved a remission has 
been disappointing, with many patients evolving insulin 
resistance or showing metabolic deterioration after more 
than 1 year on immunosuppression.23 Additionally. the 
studies indicated that the autoimmune process was not 
permanently interrupted by immunosuppression in that 
patients who discontinued cyclosporine came out of remis-
sion.24 Nevertheless. results of these trials led to the 
hypothesis that earlier intervention might be more effec-
tive in prevention or cure. 
FK 506 is a powerful new immunosuppressive drug 
currently under investigation in the field of organ trans-
plantation. It is approximately 100 times more potent an 
immunosuppressive agent than CyA on a weight basis.25 
There is some clinical evidence that it may be useful in the 
treatment of autoimmune disease in man.26•27 In addition. 
in vitro studies suggest a favorable profile on islet func-
tion.28-30 and it allowed for the first long-term successful 
outcomes in the field of islet cell transplantation.31 More-
over, FK 506 prevents the onset of diabetes in well-
established animal models of type ~ tll,abetes mellitus.32•33 
Based on the wealth of clinical information available from 
the cyclosporine trials. as well as these preliminary en-
couraging results in animal models. a pilot trial to test the 
efficacy and safety of this agent in new onset diabetes has 
recently been undertaken. 
AIMS 
Our aim was to determine if intervention with FK 506 will 
allow for sustained complete remissions of new-onset 
diabetes in a significant number of patients enrolled early 
in an immune intervention trial with this agent. 
METHODS 
The trial design is randomized and placebo controlled. Patients 
are currently enrolled based on assignment by a computer ran-
dom-number generator. Neither patients nor their referring phy-
sicians know which treatment limb the patient is assigned to. 
Physicians must be willing to suspend insulin use if clinically 
indicated and to work closely with the study team. The approved 
age group for the study is 13 to 45 years. Exclusion criteria include 
> 7 days of insulin treatment. > 10% loss of premorbid body 
weight. obesity. alcohol or drug abuse. pancreatic disease. kidney 
disease. malignancy. pregnancy. refusal to use an effective birth 
control method. multiple first-degree relatives with type II diabe-
tes. serious infection at time of onset. serious underlying medical 
illness. use of medications that may influence glucose tolerance. 
and psychiatric illness or compliance problems. 
Criteria for Remission 
Complete remission is indicated by HbAlc. within 2 SD of 
normal. fasting glucose < 140 mgldL. 2-hour postprandial glucose 
< 150 mgldL. and off insulin with a nondiabetic oral glucose 
tolerance test. A partial remission is indicated by one who 
achieves these goals. but on oral agents. or a person who fulfills all 
other criteria. yet has a diabetic oral glucose tolerance test. 
Patients who fulfill these criteria but remain on low-dose insulin 
will not be considered to be in remission. even if they sustain 
C-peptide secretion over time. 
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Fig 1. Primary reasons for patient exclusion from the FK 506 trial 
(83 patients screened). 
Treatment 
FK 506, or a look-alike placebo. is given orally 0.15 mg/kg BID. 
initially with subsequent adjustments made based on the patient's 
symptoms. trough levels. and/or toxicity profile. A 6-callkg oral 
liquid mixed meal (Sustacal) is used to assess endogenous Insulin 
secretory capacity. The protocol calls for an oral glucose toler-
ance test 6 to 8 weeks after stopping insulin if criteria for remission 
are met. 
RESULTS 
To date. 83 patient referrals have been made (Fig 1). Of 
these, 35 (42%) were primarily rejected because they were 
referred too late, 16 (19%) were too young. 1 0%) were too 
01d,5 (6%) were prediabetic. 3 (4%) had serious infections 
or histories of malignancy. 2 (2%) were excluded for strong 
suspicion of type II diabetes, and 2 (2%) for psychosocial 
reasons. Fourteen patients (17%), who were otherwise 
eligible, rejected the study for fear of potential toxicity or 
for concerns about the placebo nature of the trial. Thus far. 
five patients, aged 17 to 43. have been entered into the 
trial. One patient was accepted past the 7-day limit. At 
least one patient has been entered into each limb. The 
characteristics of patients entered into the trial are shown 
in Table I. Thus far, two patients have recently suspended 
the use of insulin. The treatment groups these patients are 
in are not reported herein to preserve the blind nature of 
the trial. 
Side Effects 
Reported side effects have included headache. fine tremor. 
ftushing sensation, heat and cold insensitivity and arthral-
Table 1. Characteristics of Pattent. In the FK 506 New-Onset 
DIDtes Trial 
Fasting/Stirn 
C·PepIIde 
Insulin Ax HBA1c(%) (0.46-1.59 
Patient Age Sex (Days) (nl.:3-6.9) pmallml) Statui 
1 17 M 4 11.8 0.3010.59 On Insulin 
2 22 F 1 6.7 0.67/1.3 On Insulin 
3 43 M 18 9.9 1.2012.2 Oft Insulin 
4 38 M 3 10.6 0.1610.48 Oft Insutin 
5 17 M 7 14.4 0.2910.38 On Insulin 
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gias. There have been two infections treated with antibi-
otics. one in each group: one sinusitis and one strep throat. 
A dose-related acute rise in baseline creatinine has been 
observed in some patients as has been elevation of serum 
potassium. No patient has discontinued the use of the drug 
for toxicity reasons. 
CONCLUSIONS 
A clinical trial has begun to assess: (I) if early entry into a 
trial with the potent new immunosuppressant, FK 506. can 
induce complete or significant partial remission in new-
onset diabetes; and (2) if remissions can be sustained over 
time. The initial response has been encouraging, but re-
cruitment this early is difficult. and early referrals will be 
critical to answer this question. The question of whether a 
cure is still possible at clinical onset of the disease is an 
important one. since type I diabetes appears to be increas-
ing in our population. Current methods of screening for 
prediabetes are not 100% sensitive and specific. and would 
not be cost-effective to be applied to the low-risk general 
population. where most cases of diabetes will continue to 
occur. Thus, development of safe and effective methods of 
single agents. or combinations that could induce sustained 
remissions in patients with new onset diabetes, will con-
tinue to be of clinical benefit. 
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